Navigation Links
Milnacipran Demonstrated Significant Improvement in Pain and the Core Symptoms of Fibromyalgia Syndrome, Data Show
Date:11/8/2007

re assessed for all patients at both the three- and six-month visits.

Patients who completed the full six-months of treatment in Study FMS-031 were eligible to enroll in a multi-center, dose-blinded, extension study designed to evaluate durability of response up to one year. A total of 449 patients were either maintained at 200 mg/day (n=209) or re-randomized to 100 mg/day (n=48) or 200 mg/day (n=192) for an additional six months. Efficacy assessments included change in pain, as measured using a paper visual analog scale, and multidimensional symptomatic improvements, as measured using the Fibromyalgia Impact Questionnaire and PGIC.

Data Highlights

Results reported below are based on observed cases, which include only patients who were evaluable at the landmark visit. In study MLN-MD-02, there were 713 evaluable patients for the fibromyalgia syndrome and pain analyses (n=236 for 100 mg, n=215 for 200 mg, and n=262 for placebo).

In study FMS-031, at the three-month visit there were 549 evaluable patients for the syndrome analysis (n=134 for 100 mg, n=259 for 200 mg, and n=156 for placebo), and 553 evaluable patients for the pain analysis (n=135 for 100 mg, n=260 for 200 mg, and n=158 for placebo). At the six-month visit there were 488 evaluable patients for the fibromyalgia syndrome analysis (n=120 for 100 mg, n=229 for 200 mg, and n=139 for placebo), and 491 evaluable patients for the fibromyalgia pain analysis (n=121 for 100 mg, n=230 for 200 mg, and n=140 for placebo).

Composite responder rates for fibromyalgia syndrome (pain, PGIC, and SF-36 PCS)

-- A statistically significant number of patients treated with milnacipran

during Study MLN-MD-02 met the composite syndrome responder criteria

(25% and 26% for the milnacipran 100 mg and 200 mg groups,

respectively) compared to patients treated with placebo (13%).

-- A statistically significant number of patients treated with milnacipran

durin
'/>"/>

SOURCE Forest Laboratories, Inc. and Cypress Bioscience, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Nebivolol Lowers Blood Pressure in Mild-to-Moderate Hypertensive Patients as Demonstrated in a Study Published in the Journal of Clinical Hypertension
2. Versatility of 454 Sequencing(TM) Demonstrated in Three Publications in Science Last Week
3. Clinical Benefits Demonstrated with Low-Dose GATTEX(TM) in Phase 3 Short Bowel Syndrome Study
4. Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
5. UPDATE: Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
6. Data Presented at the American Heart Association Scientific Sessions 2007 Demonstrated Increased HDL with ACTOS(R) (pioglitazone HCl) Slowed the Progression of Carotid Intima-Media Thickness in Patients with Type 2 Diabetes
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. DEFLUX(R) Significantly Reduces Urinary Tract Infections in Children With Vesicoureteral Reflux
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS)
11. Nexavar Significantly Improved Overall Survival in Phase 3 Asia-Pacific Liver Cancer Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... , May 22, 2015  In a sweeping ... the U.S., T1D Exchange researchers conclude that ... type 1 diabetes across all age groups, but especially ... most up-to-date picture of diabetes treatment, underscoring the need ... and technologies that can help type 1 patients achieve ...
(Date:5/22/2015)... 2015  China Nepstar Chain Drugstore Ltd. (NYSE: NPD ... chain in China based on ... resignation of Mr. Fuxiang Zhang as the ... Ms. Rebecca Yingnan Zhang has been appointed ... directors, effective immediately. Meanwhile, Ms. Zhang resigned from the ...
(Date:5/21/2015)... , May 21, 2015 ... announced the addition of the "North American ... Graft), by Application (Surgical Wound, & Ulcer), by ... to 2019" report to their offering. ,     ... care market is estimated to grow at a ...
Breaking Medicine Technology:Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 2Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 3Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 4Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 5China Nepstar Chain Drugstore Ltd. Announces Management Change and New Director Appointment 2China Nepstar Chain Drugstore Ltd. Announces Management Change and New Director Appointment 3North American Active Wound Care Market 2015-2019 with Smith and Nephew, Molyncke HealthCare & ConvaTec Dominating 2
(Date:5/25/2015)... MA (PRWEB) May 25, 2015 A recent ... 2015 states 1,000 persons have died as a direct result ... 2014. This marks a 33% rise in overdose deaths attributed ... Charlie Baker, “This issue doesn’t care about geography. This issue ... This issue doesn’t care about class.” As the state of ...
(Date:5/25/2015)... 25, 2015 Join Fiona's Soccer Camp at ... instructional clinic. Irish National Player, Fiona O'Sullivan will be ... a taste of her coaching style. Fiona has three camps ... in Novato are at Lynwood Elmentary School (June 15-19) and ... School - June 6th, 2015 - 1:00-3:00pm. Bring a Soccer ...
(Date:5/25/2015)... 2015 Decora Preset 60 Minute Countdown ... available on ‘The Hardware City.’ The product helps in automatically ... a time and the related electronic device is automatically turned ... of the company said, “We are glad that this amazing ... can buy Countdown Timer Switch in just a few clicks. ...
(Date:5/24/2015)... May 24, 2015 For people who ... Chinese Enterokinase Industry, 2009-2019 Market Research Report would be ... an exhaustive study on the present market scenario of ... into the growing Chinese market of this industry. The ... overall status of the manufacturers in this industry. The ...
(Date:5/24/2015)... New York, New York (PRWEB) May 24, 2015 ... of testosterone treatment lawsuits ( http://www.testosteronelawsuithub.com/ ) has ... discuss the progress of the multidistrict litigation. According ... Court, Northern District of Illinois, the Conference will ... p.m. (In re: Testosterone Replacement Therapy Product Liability ...
Breaking Medicine News(10 mins):Health News:Opioid Deaths Increase by 33 Percent Since 2012 in Mass. 2Health News:US Sports Camps and Nike Soccer Camps Offer Complimentary Instructional Clinic with Fiona's Soccer Camp 2Health News:Leviton's Decora 60 Minute Countdown Timer Available On ‘The Hardware City’ 2Health News:Global and Chinese Enterokinase Industry 2009-2019 Market Research Report Now Available at RnRMarketResearch.com 2Health News:Global and Chinese Enterokinase Industry 2009-2019 Market Research Report Now Available at RnRMarketResearch.com 3Health News:Global and Chinese Enterokinase Industry 2009-2019 Market Research Report Now Available at RnRMarketResearch.com 4Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Look Ahead to June Conference in Federal Multidistrict Litigation 2Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Look Ahead to June Conference in Federal Multidistrict Litigation 3
... , WEDNESDAY, May 18 (HealthDay News) -- Although ... offer no benefit to patients suffering from pulmonary arterial ... blood pressure in the arteries of the lungs, according ... by the U.S. National Institutes of Health, researchers divided ...
... By Jenifer Goodwin HealthDay Reporter , WEDNESDAY, ... younger are now being treated for autism in Massachusetts, a ... born between 2001 and 2005 was enrolled in early intervention ... according to the study. Over the five-year period, the ...
... absorbed from the sun, plays a role in protection against ... has shown that children who live in colder, wetter cities ... since there are fewer hours of sunlight in such places. ... it,s also dangerous to avoid it. There has to be ...
... associated with outsized, supercooled, superconducting magnets, is one of ... study everything from alcohols to proteins to such frontiers ... cousin, magnetic resonance imaging (MRI), is as loud as ... for a wide range of medical conditions. ...
... NYU Langone Medical Center, one of the nation,s premier academic ... Medicine, NYU Physician, is now available as a free iPad ... published three times a year, provides news and insights about ... Each issue features a trio of in-depth articles focused on ...
... ARBOR, Mich. About half of prostate cancers have a ... a new class of cancer-fighting drugs, a new study from ... drugs, called PARP inhibitors, are currently being tested in breast ... which are found in up to 10 percent of all ...
Cached Medicine News:Health News:Standard Heart Drugs Won't Ease Pulmonary Hypertension 2Health News:Massachusetts Study Shows Sharp Rise in Early Autism Diagnoses 2Health News:Massachusetts Study Shows Sharp Rise in Early Autism Diagnoses 3Health News:Sun protects against childhood asthma 2Health News:Nuclear magnetic resonance with no magnets 2Health News:Nuclear magnetic resonance with no magnets 3Health News:Nuclear magnetic resonance with no magnets 4Health News:Nuclear magnetic resonance with no magnets 5Health News:Nuclear magnetic resonance with no magnets 6Health News:Half of prostate cancers could potentially benefit from new type of cancer drugs, U-M study finds 2
Used to obtain biopsy specimens from pathological lesions in the ureter, renal pelvis, infundibula, or calyces. Supplied sterile in peel-open packages. Intended for one-time use....
Inquire...
Used to obtain tissue biopsy under direct vision. Cup Biopsy Forceps are designed for use through rigid or flexible endoscopes. Supplied sterile in peel-open packages. Intended for one-time use....
... Brasseler USA™ MicroLine™ Small Bone Power ... operation while performing under the most ... system developed for small bone osteotomies ... Sagittal Saw (Extended Length Available), Oscillating ...
Medicine Products: